Aspirin acute MI indication public education effort by FDA urged in Bayer comments.
This article was originally published in The Tan Sheet
ASPIRIN ACUTE MI INDICATION PUBLIC EDUCATION EFFORTS BY FDA RECOMMENDED by Bayer Consumer Care in Sept. 11 comments on the agency's recently proposed professional labeling claim for aspirin. Published June 13, FDA's proposal would amend the tentative final monograph for OTC internal analgesic, antipyretic and antirheumatic drugs to include professional labeling of aspirin products for reduced "risk of vascular mortality in people with suspected acute myocardial infarction (MI)" ("The Tan Sheet" June 17, p. 3).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC